Cargando…
Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Dialysis Patients: A Nationwide Data Survey and Propensity Analysis
Long-term benefit of using a renin–angiotensin–aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of...
Autores principales: | Wu, Cho-Kai, Yang, Yao-Hsu, Juang, Jyh-Ming Jimmy, Wang, Yi-Chih, Tsai, Chia-Ti, Lai, Ling-Ping, Hwang, Juey-Jen, Chiang, Fu-Tien, Chen, Pau-Chung, Lin, Jiunn-Lee, Lin, Lian-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602640/ https://www.ncbi.nlm.nih.gov/pubmed/25621694 http://dx.doi.org/10.1097/MD.0000000000000424 |
Ejemplares similares
-
Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study
por: Hsieh, Yu-Cheng, et al.
Publicado: (2016) -
Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021) -
Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2017) -
Angiotensin converting enzyme inhibitors and risk of lung cancer: A systematic review and meta-analysis
por: Batais, Mohammed, et al.
Publicado: (2021) -
Prognostic value of elevated plasma angiotensin-converting enzyme 2 in cardiometabolic diseases: A review
por: Zhou, Gang, et al.
Publicado: (2023)